AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference
January 04 2022 - 8:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical
stage biotechnology company focused on the development and
commercialization of adeno-associated virus (AAV)-based gene
therapies for the treatment of rare and debilitating diseases with
an initial focus on inherited retinal diseases (IRDs), today
announced that Sue Washer, President & Chief Executive Officer,
and Susan Schneider M.D., Chief Medical Officer, will participate
in a fireside chat at the H.C. Wainwright Virtual BioConnect
Conference held January 10 – 13, 2022.
The fireside chat will be available to view
on-demand beginning Monday, January 10, 2021 at 7:00AM ET through
the entirety of the conference and available by visiting
http://ir.agtc.com/events-and-presentations.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies with the
potential to address real patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with an inherited retinal
disease. AGTC has active clinical trials in X-linked retinitis
pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
Its preclinical programs build on the Company’s industry leading
AAV manufacturing technology and scientific expertise. AGTC is
advancing multiple important pipeline candidates to address
substantial unmet clinical need in optogenetics, otology and CNS
disorders, including entering into strategic collaborations with
companies including Otonomy, Inc., a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, and Bionic Sight, LLC, an innovator in the emerging
field of optogenetics and retinal coding. For more information,
please visit https://agtc.com/.
IR Contact: David Carey
(IR)Lazar FINN PartnersT: (212)
867-1768david.carey@finnpartners.com
Corporate Contact:Jonathan
LieberChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5778 jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024